Observational studyJapanese journal of clinical oncology2022

The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.

Yuichiro Ohe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.